IBL HealthCare Valuation
Is IBLHL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IBLHL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IBLHL's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IBLHL's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IBLHL?
Key metric: As IBLHL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is IBLHL's PS Ratio? | |
|---|---|
| PS Ratio | 0.9x |
| Sales | PK₨3.62b |
| Market Cap | PK₨3.32b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | 27.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does IBLHL's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
SHFA Shifa International Hospitals | 1x | n/a | PK₨24.0b |
SDPC Millennium Pharmacon International | 0.05x | n/a | Rp193.6b |
TM Techno Medical | 0.5x | n/a | ฿357.3m |
RAWILL R.A. Williams Distributors | 1.1x | n/a | JA$1.7b |
IBLHL IBL HealthCare | 0.9x | n/a | PK₨3.3b |
Price-To-Sales vs Peers: IBLHL is expensive based on its Price-To-Sales Ratio (0.9x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does IBLHL's PS Ratio compare vs other companies in the Asian Healthcare Industry?
| 60 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 60 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: IBLHL is good value based on its Price-To-Sales Ratio (0.9x) compared to the Asian Healthcare industry average (1.6x).
Price to Sales Ratio vs Fair Ratio
What is IBLHL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate IBLHL's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.